1-benzyl-6-bromo-3-methyl-3,4-dihydroquinazolin-2(1H)-one | 328956-25-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 1-benzyl-6-bromo-3-methyl-3,4-dihydroquinazolin-2(1H)-one
• 英文别名: 1-Benzyl-6-bromo-3,4-dihydro-3-methyl-2(1H)-quinazolinone；6-Bromo-3,4-dihydro-3-methyl-1-(phenylmethyl)-2(1H)-quinazolinone；1-benzyl-6-bromo-3-methyl-4H-quinazolin-2-one
• CAS: 328956-25-8
• 化学式: C₁₆H₁₅BrN₂O
• 分子量: 331.212
• InChiKey: NFJBHPCRUDLSFG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  23.6
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-benzyl-6-bromo-3-methyl-3,4-dihydroquinazolin-2(1H)-one 、 (甲基亚砜亚胺基)苯 在 tris-(dibenzylideneacetone)dipalladium(0) 、 caesium carbonate 、 2-二环己基磷-2,4,6-三异丙基联苯 作用下， 以 1,4-二氧六环 为溶剂， 反应 24.0h， 以38%的产率得到rac-N-(1-benzyl-3-methyl-2-oxo-1,2,3,4-tetrahydroquinazolin-6-yl)-S-methyl-S-phenylsulfoximine
  参考文献：
  名称：

  Chiral Analogues of PFI-1 as BET Inhibitors and Their Functional Role in Myeloid Malignancies

  摘要：

  Structural analogues of PFI-1 varying at the sulfur core were prepared, and their activities as BET inhibitors in myeloid cell lines and primary cells from patients with acute myeloid leukemia were studied. Docking calculations followed by molecular dynamics simulations revealed the binding mode of the newly prepared inhibitors, suggesting explanations for the observed high enantiospecificity of the inhibitory activity.

  DOI：

  10.1021/acsmedchemlett.9b00625
• 作为产物：
  描述：

  3,4-二氢-3-甲基-2(1H)-喹唑啉酮 在 N-溴代丁二酰亚胺(NBS) 、 sodium hydride 作用下， 以 二氯甲烷 、 mineral oil 为溶剂， 反应 20.33h， 生成 1-benzyl-6-bromo-3-methyl-3,4-dihydroquinazolin-2(1H)-one
  参考文献：
  名称：

  Chiral Analogues of PFI-1 as BET Inhibitors and Their Functional Role in Myeloid Malignancies

  摘要：

  Structural analogues of PFI-1 varying at the sulfur core were prepared, and their activities as BET inhibitors in myeloid cell lines and primary cells from patients with acute myeloid leukemia were studied. Docking calculations followed by molecular dynamics simulations revealed the binding mode of the newly prepared inhibitors, suggesting explanations for the observed high enantiospecificity of the inhibitory activity.

  DOI：

  10.1021/acsmedchemlett.9b00625

文献信息

• Bicyclic androgen and progesterone receptor modulator compounds and methods
  申请人：Zhi Lin

  公开号：US20050288350A1

  公开（公告）日：2005-12-29

  The present invention is directed to compounds, pharmaceutical compositions, and methods for modulating processes mediated by AR and PR. More particularly, the invention relates to nonsteroidal compounds and compositions that are high affinity, high specificity agonists, partial agonists (i.e., partial activators and/or tissue-specific activators) and antagonists for AR and PR. Also provided are methods of making such compounds and pharmaceutical compositions, as well as critical intermediates used in their synthesis.

  本发明涉及化合物、制药组合物和调节由AR和PR介导的过程的方法。更具体地，本发明涉及非甾体化合物和组合物，它们是高亲和力、高特异性的AR和PR激动剂、部分激动剂（即部分激活剂和/或组织特异性激活剂）和拮抗剂。还提供了制备这些化合物和制药组合物的方法，以及在它们的合成中使用的关键中间体。
• BICYCLIC ANDROGEN AND PROGESTERONE RECEPTOR MODULATOR COMPOUNDS AND METHODS
  申请人：LIGAND PHARMACEUTICALS INCORPORATED

  公开号：EP1212303A2

  公开（公告）日：2002-06-12
• JP2003508387A
  申请人：——

  公开号：JP2003508387A

  公开（公告）日：2003-03-04
• US6566372B1
  申请人：——

  公开号：US6566372B1

  公开（公告）日：2003-05-20
• US6964973B2
  申请人：——

  公开号：US6964973B2

  公开（公告）日：2005-11-15